



March 3, 2017

Flexion Therapeutics to Present at Upcoming Investor Conferences

BURLINGTON, Mass., March 03, 2017 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that Michael Clayman, M.D., President and Chief Executive Officer, will present at two upcoming investor conferences:

- | **Raymond James 38th Annual Institutional Investors Conference**
Dr. Clayman will present on Tuesday, March 7, 2017 at 7:30 a.m. EST

- | **Cowen & Company 37th Annual Health Care Conference**
Dr. Clayman will present on Wednesday, March 8, 2017 at 8:00 a.m. EST

To access the live webcast and subsequent archived recordings for the presentations, please visit the Flexion website at <http://flexiontherapeutics.com/>.

About Flexion Therapeutics

Flexion is a specialty pharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA). The company's lead product candidate, Zilretta™ (FX006), is being investigated for its potential to provide improved analgesia for the millions of U.S. patients who receive intra-articular injections for OA related knee pain annually.

Corporate Contacts:

Fred Driscoll
Chief Financial Officer
Flexion Therapeutics, Inc.
T: 781-305-7763
fdriscoll@flexiontherapeutics.com

Scott Young
Sr. Director, Corporate Communications & Investor Relations
Flexion Therapeutics, Inc.
T: 781-305-7194
syoung@flexiontherapeutics.com